|
|||||
|
|
Nivolumab in Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs |
|
| Authors: | Jacopo Giuliani Andrea Bonetti |
| Institution: | Department of Oncology, Mater Salutis Hospital, Veneto, Legnago, Italy |
| Abstract: | |
| Keywords: | Cost of drugs ESMO-MCBS Randomized phase 3 trials Second-line therapy Targeted therapies |
| 本文献已被 ScienceDirect 等数据库收录！ | |